Physician profile
Fiona Eapen
NPI 1710112289
$11,553.60
in general payments reported to CMS, 2019-2025
29 companies · $2,485 in 2025
The $2,485 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,994 · 2022: $959 · 2023: $3,677 · 2024: $2,439 · 2025: $2,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,447 · Consulting Fee: $2,750 · Education: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,447.06 |
| Consulting Fee | $2,750.00 |
| Education | $403.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $2,780.30 | 2023-2025 | Clindacin Etz, Neo-Synalar, Sumadan Wash |
| Janssen Biotech, INC. | $1,113.28 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $1,031.47 | 2021-2025 | Absorica Ld, Winlevi, Ilumya |
| Abbvie INC. | $672.11 | 2021-2025 | |
| Almirall LLC | $599.88 | 2021-2025 | Klisyri |
| Leo Pharma INC. | $565.34 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $558.01 | 2023-2025 | Sotyktu |
| Pfizer INC. | $471.12 | 2021-2025 | |
| Lilly USA, LLC | $449.58 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Arcutis Biotherapeutics, INC. | $423.61 | 2023-2025 | Zoryve |
| Amgen INC. | $381.53 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $336.38 | 2021-2025 | Dupixent |
| Ucb, INC. | $305.39 | 2021-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $293.57 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $288.54 | 2021-2025 | Aklief, Nemluvio |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $245.89 | 2021-2025 | Opzelura |
| Botanix Sb INC | $229.73 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $217.00 | 2021-2025 | |
| Genzyme Corporation | $186.88 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Organon LLC | $55.53 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.69 | 2023-2025 | Spevigo |
| Journey Medical Corporation | $44.54 | 2022-2025 | |
| Epi Health, LLC | $39.35 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $33.14 | 2021 | |
| Strata Skin Sciences, INC. | $32.90 | 2024-2025 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.41 | 2021-2023 | Arazlo |
| Sandoz INC. | $17.86 | 2021 | |
| Dermira, INC. | $17.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.